Literature DB >> 20185928

Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies.

Hyun Soon Lee1, Chi Young Song.   

Abstract

Injured podocytes proliferate in cellular focal segmental glomerulosclerosis (FSGS), collapsing FSGS and crescentic glomerulonephritis, where TGF-beta(1) is overexpressed in hyperplastic podocytes. Yet effects of podocyte TGF-beta on podocyte growth and development of glomerulosclerosis have not been clearly defined. TGF-beta activates Smads, Ras/extracellular signal-regulated kinase (ERK) and phosphatidyl inositol-3-kinase (PI3K) pathways in podocytes, of which the major TGF-beta/Smad signaling pathway appears to override the minor TGF-beta-induced Ras/ERK/PI3K pathways. We provide evidence that increasedTGF-beta/Smad signaling activity by hyperplastic podocytes may lead to mesangial cell matrix overproduction and eventually to podocyte apoptosis and/or detachment, culminating in the development of glomerulosclerosis. In this regard, TGF-beta, which is overexpressed by hyperplastic podocytes, may play an important role for the cellular and collapsing variants of FSGS to evolve into the classic FSGS pattern. In contrast, podocyte proliferation that is induced by Ras/ERK signaling activity in proliferative podocyte diseases seems to be mostly independent of TGF-beta(1) activity. Collectively, these data bring new insights into our understanding of the overexpression of TGF-beta in hyperplastic podocytes in progressive glomerular diseases. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185928     DOI: 10.1159/000285844

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  17 in total

1.  Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Jianming Qiu; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

2.  TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.

Authors:  Toru Sakairi; Yoshifusa Abe; Jeffrey B Kopp
Journal:  Nephrol Dial Transplant       Date:  2011-03-04       Impact factor: 5.992

Review 3.  Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Authors:  Judit Gordon; Jeffrey B Kopp
Journal:  Adv Chronic Kidney Dis       Date:  2011-07       Impact factor: 3.620

4.  TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway.

Authors:  Yoshifusa Abe; Toru Sakairi; Craig Beeson; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-18

Review 5.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

6.  A novel podocyte protein, R3h domain containing-like, inhibits TGF-β-induced p38 MAPK and regulates the structure of podocytes and glomerular basement membrane.

Authors:  Takahiro Ishikawa; Minoru Takemoto; Yoshihiro Akimoto; Aki Takada-Watanabe; Kunimasa Yan; Kenichi Sakamoto; Yoshiro Maezawa; Miyuki Suguro; Liqun He; Karl Tryggvason; Christer Betsholtz; Koutaro Yokote
Journal:  J Mol Med (Berl)       Date:  2021-02-23       Impact factor: 4.599

7.  Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.

Authors:  Ken-Ichi Aihara; Yasumasa Ikeda; Shusuke Yagi; Masashi Akaike; Toshio Matsumoto
Journal:  Cardiol Res Pract       Date:  2010-12-28       Impact factor: 1.866

8.  Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy.

Authors:  Michal Herman-Edelstein; Merlin C Thomas; Vicki Thallas-Bonke; Moin Saleem; Mark E Cooper; Phillip Kantharidis
Journal:  Diabetes       Date:  2011-04-26       Impact factor: 9.461

9.  A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.

Authors:  Howard Trachtman; Fernando C Fervenza; Debbie S Gipson; Peter Heering; David R W Jayne; Harm Peters; Stefano Rota; Giuseppe Remuzzi; L Christian Rump; Lorenz K Sellin; Jeremy P W Heaton; James B Streisand; Marjie L Hard; Steven R Ledbetter; Flavio Vincenti
Journal:  Kidney Int       Date:  2011-03-02       Impact factor: 10.612

10.  Invariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosis.

Authors:  Rafael L Pereira; Vanessa O Reis; Patricia Semedo; Bruna N Buscariollo; Cassiano Donizetti-Oliveira; Marcos A Cenedeze; Maria Fernanda Soares; Alvaro Pacheco-Silva; Paul B Savage; Niels O S Câmara; Alexandre C Keller
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.